Safety of prolonged Doxil administration in recurrent gynecologic cancers

Franco M. Muggia(NYU Langone Health), Anne Hamilton(Royal Women's Hospital), Howard S. Höchster(Rutgers, The State University of New Jersey), Joan Sorich, Kathleen McCaffrey(NYU Langone Health), E. Kim(NYU Langone Health), R. Green(NYU Langone Health), D. Mirchandani, Andrea Downey(University of New Mexico), Mei-Yao Ho(NYU Langone Health)
Journal of Clinical Oncology
July 15, 2004
10.1200/jco.2004.22.90140.5055
Cited by 7

Related Papers

Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
|JAMA|2017|891
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
|Journal of Clinical Oncology|2008|623
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
|Journal of Clinical Oncology|2020|391